Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection with ex vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

The purpose of this study is to test whether giving an experimental cell product can treat viral infection in patients who have conditions that cause the poor function of their immune system. The patients with infections caused by viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK and JC polyomaviruses (PyVs) virus may participate in this study. The cell product is called rapidly generated virus-specific T cells (R-MVST). R-MVST cells will be manufactured in our laboratory at Columbia University Irving Medical Center. This cell product has not been approved by the Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

• Must have been diagnosed with a viral infection caused by impaired function of the immune system after the hematopoietic stem cell transplant or other conditions that lead to diminished immunity.
• Looking for subjects that have been treated with a steroid like prednisone or an equivalent.
• Must be 18 years or older and capable of providing informed consent.